Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of AFFITOPE AD02 in early Alzheimer's disease
2009-016504-22Phase 2Completed
- Sponsor
- AFFiRiS
- Start
- Feb 2010
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of affitope ad02 in Alzheimer's disease (AD) (6 arms), sponsored by AFFiRiS. Primary endpoint: Clinical activity in cognitive and functional domains. Started Feb 2010; status: completed.
02
Drugs
affitope ad02
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-016504-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016504-22.